135 related articles for article (PubMed ID: 38278432)
1. Race, Genotype, and Prognosis in Black Patients With Transthyretin Cardiac Amyloidosis.
Khedraki R; Saef J; Martens P; Martyn T; Sul L; Hachamovitch R; Ives L; Estep JD; Tang WHW; Hanna M
Am J Cardiol; 2024 Apr; 216():66-76. PubMed ID: 38278432
[TBL] [Abstract][Full Text] [Related]
2. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS).
Bhuiyan T; Helmke S; Patel AR; Ruberg FL; Packman J; Cheung K; Grogan D; Maurer MS
Circ Heart Fail; 2011 Mar; 4(2):121-8. PubMed ID: 21191093
[TBL] [Abstract][Full Text] [Related]
3. The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients.
Dungu J; Sattianayagam PT; Whelan CJ; Gibbs SD; Pinney JH; Banypersad SM; Rowczenio D; Gilbertson JA; Lachmann HJ; Wechalekar A; Gillmore JD; Hawkins PN; Anderson LJ
Am Heart J; 2012 Jul; 164(1):72-9. PubMed ID: 22795285
[TBL] [Abstract][Full Text] [Related]
4. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
[TBL] [Abstract][Full Text] [Related]
5. Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
Madhani A; Sabogal N; Massillon D; Paul LD; Rodriguez C; Fine D; Helmke S; Winburn M; Kurian D; Raiszadeh F; Teruya S; Cohn E; Einstein AJ; Miller EJ; Connors LH; Maurer MS; Ruberg FL
J Am Heart Assoc; 2023 Aug; 12(15):e028973. PubMed ID: 37486082
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).
Ruberg FL; Maurer MS; Judge DP; Zeldenrust S; Skinner M; Kim AY; Falk RH; Cheung KN; Patel AR; Pano A; Packman J; Grogan DR
Am Heart J; 2012 Aug; 164(2):222-228.e1. PubMed ID: 22877808
[TBL] [Abstract][Full Text] [Related]
7. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis.
Connors LH; Prokaeva T; Lim A; Théberge R; Falk RH; Doros G; Berg A; Costello CE; O'Hara C; Seldin DC; Skinner M
Am Heart J; 2009 Oct; 158(4):607-14. PubMed ID: 19781421
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).
Phull P; Sanchorawala V; Connors LH; Doros G; Ruberg FL; Berk JL; Sarosiek S
Amyloid; 2018 Mar; 25(1):62-67. PubMed ID: 29424556
[TBL] [Abstract][Full Text] [Related]
10. Clinical comparison of V122I genotypic variant of transthyretin amyloid cardiomyopathy with wild-type and other hereditary variants: a systematic review.
Goyal A; Lahan S; Dalia T; Ranka S; Bhattad VB; Patel RR; Shah Z
Heart Fail Rev; 2022 May; 27(3):849-856. PubMed ID: 33768376
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cardiac involvement, extracardiac manifestations and outcomes between homozygote and heterozygote transthyretin p.Val142Ile (V122I) variant in patients with hereditary transthyretin amyloidosis: a cohort study.
Albenque G; Bézard M; Kharoubi M; Odouard S; Lunati A; Poullot E; Zaroui A; Teiger E; Hittinger L; Audard V; El Karoui K; Funalot B; Fanen P; Damy T; Oghina S
Amyloid; 2023 Dec; 30(4):407-415. PubMed ID: 37377439
[TBL] [Abstract][Full Text] [Related]
12. Afro-Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I Cardiac Amyloidosis.
Dungu JN; Papadopoulou SA; Wykes K; Mahmood I; Marshall J; Valencia O; Fontana M; Whelan CJ; Gillmore JD; Hawkins PN; Anderson LJ
Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618855
[TBL] [Abstract][Full Text] [Related]
13. Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?
Razvi Y; Ioannou A; Patel RK; Chacko L; Karia N; Riefolo M; Porcari A; Rauf MU; Starr N; Ganesananthan S; Blakeney I; Kaza N; Filisetti S; Bolhuis RE; Rowczenio D; Gilbertson J; Hutt D; Mahmood S; Lachmann HJ; Wechalekar AD; Kotecha T; Knight DS; Coghlan JG; Petrie A; Whelan CJ; Venneri L; Martinez-Naharro A; Hawkins P; Fontana M; Gillmore JD
Eur J Heart Fail; 2024 Feb; 26(2):383-393. PubMed ID: 37953725
[TBL] [Abstract][Full Text] [Related]
14. Cardiac transthyretin amyloidosis.
Dungu JN; Anderson LJ; Whelan CJ; Hawkins PN
Heart; 2012 Nov; 98(21):1546-54. PubMed ID: 22888163
[TBL] [Abstract][Full Text] [Related]
15. The amyloidogenic V122I transthyretin variant in elderly black Americans.
Quarta CC; Buxbaum JN; Shah AM; Falk RH; Claggett B; Kitzman DW; Mosley TH; Butler KR; Boerwinkle E; Solomon SD
N Engl J Med; 2015 Jan; 372(1):21-9. PubMed ID: 25551524
[TBL] [Abstract][Full Text] [Related]
16. Relation of Body Mass Index to Transthyretin Cardiac Amyloidosis Particularly in Black and Hispanic Patients (from the SCAN-MP Study).
Poterucha TJ; Kurian D; Raiszadeh F; Teruya S; Elias P; Kogan R; Chiuzan C; Einstein AJ; Ruberg FL; Maurer MS
Am J Cardiol; 2022 Aug; 177():116-120. PubMed ID: 35705430
[TBL] [Abstract][Full Text] [Related]
17. Low Prevalence of Clinically Apparent Cardiac Amyloidosis Among Carriers of Transthyretin V122I Variant in a Large Electronic Medical Record.
Agbor-Etang BB; Okafor HE; Farber-Eger EH; Wells QS
Am J Med; 2021 Feb; 134(2):e98-e100. PubMed ID: 32866461
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
[TBL] [Abstract][Full Text] [Related]
19. Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis.
Batra J; Rosenblum H; Cappelli F; Zampieri M; Olivotto I; Griffin JM; Saith SE; Teruya S; De Los Santos J; Argiro A; Burkhoff D; Perfetto F; Maurer MS
J Card Fail; 2022 Jun; 28(6):950-959. PubMed ID: 34974181
[TBL] [Abstract][Full Text] [Related]
20. Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry.
Parker MM; Damrauer SM; Tcheandjieu C; Erbe D; Aldinc E; Hawkins PN; Gillmore JD; Hull LE; Lynch JA; Joseph J; Ticau S; Flynn-Carroll AO; Deaton AM; Ward LD; Assimes TL; Tsao PS; Chang KM; Rader DJ; Fitzgerald K; Vaishnaw AK; Hinkle G; Nioi P
Sci Rep; 2021 Jun; 11(1):11645. PubMed ID: 34079032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
